Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nerviano HER3-ADC
- Development stage
- Preclinical
- Lead developer
- Nerviano Medical Sciences
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Nerviano HER3-ADC is a preclinical antibody-drug conjugate (ADC) developed by Nerviano Medical Sciences. It consists of a monoclonal antibody targeting Human Epidermal Growth Factor Receptor 3 (HER3/ERBB3) conjugated to a proprietary duocarmycin-derivative payload. Unlike many current ADCs that utilize topoisomerase I inhibitors (e.g., deruxtecan), this candidate employs a DNA-alkylating duocarmycin payload to overcome resistance mechanisms, particularly in tumors that have progressed after treatment with Topo I-based ADCs. The duocarmycin derivative acts as a potent cytotoxic agent by alkylating DNA in the minor groove, leading to cell death in HER3-expressing cancer cells. It is currently being investigated for the treatment of therapy-resistant solid tumors, including breast cancer, colorectal cancer (CRC), and non-small cell lung cancer (NSCLC).
- Other names
- HER3-duocarmycin ADCHER-3-duocarmycin ADCHER 3-duocarmycin ADCNerviano HER3-ADC-duocarmycin
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on Nerviano HER3-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nerviano HER3-ADC.